|Disease Group:||Advanced Cancers; Solid Tumors|
|Phase of Study:||Phase I|
|Treatment Location:||Only at MDACC|
|Estimated Length of Stay in Houston:||During each cycle, the patient will be admitted for 3 days (d1 to d3) to have |
intravenous bevacizumab, continuous intravenous infusion of paclitaxel and
intraperitoneal oxaliplatin; and then for 2 days (d8 to d9) to have
|Return Visit:||The patient will have office visit once every 21 days or sooner as needed, and |
be admitted for treatment as mentioned above.
|Home Care:||The initial or loading doses of bevacizumab and paclitaxel will be given in the |
clinic. Subsequent doses may be given at home.